federal_register: 2013-15250

All Federal Register documents (rules, proposed rules, notices, presidential documents) from 1994 to present. Nearly 1M documents with full-text search.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

document_number title type abstract publication_date pub_year pub_month html_url pdf_url agency_names agency_ids excerpts
2013-15250 Draft Guidance for Industry on Expedited Programs for Serious Conditions-Drugs and Biologics; Availability Notice The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Expedited Programs for Serious Conditions--Drugs and Biologics." The purpose of this draft guidance is to provide a single resource for information on FDA's policies and procedures related to expedited drug development and review programs. The following programs are intended to facilitate and expedite development and review of new drugs to address unmet medical need in the treatment of serious or life-threatening conditions (expedited programs): Fast track designation, breakthrough therapy designation, accelerated approval, and priority review designation. 2013-06-26 2013 6 https://www.federalregister.gov/documents/2013/06/26/2013-15250/draft-guidance-for-industry-on-expedited-programs-for-serious-conditions-drugs-and-biologics https://www.govinfo.gov/content/pkg/FR-2013-06-26/pdf/2013-15250.pdf Health and Human Services Department; Food and Drug Administration 221,199 The Food and Drug Administration (FDA) is announcing the availability of a draft guidance for industry entitled "Expedited Programs for Serious Conditions--Drugs and Biologics." The purpose of this draft guidance is to provide a single resource for...

Links from other tables